Related Experiment Videos
Adapting the dialysis unit to increased hematocrit levels
1Department of Hypertension/Nephrology, Cleveland Clinic Foundation, OH 44195, USA.
Summary
Erythropoietin (epoetin) therapy significantly improves well-being in dialysis patients by reducing anemia. Long-term studies show fears of hypertension and fistula clotting are largely unfounded, allowing for optimized patient outcomes.
Area of Science:
- Nephrology
- Hematology
Background:
- Recombinant human erythropoietin (epoetin) revolutionized nephrology practice, particularly for dialysis patients.
- Long-term studies have established parameters for optimizing epoetin therapy and patient outcomes.
Purpose of the Study:
- To address the persistent question of why average hematocrit levels in dialysis patients remain around 30%.
- To evaluate concerns regarding potential increased morbidity at higher hematocrit levels, including hypertension and fistula clotting.
Main Methods:
- Review of long-term studies and postmarketing data on epoetin therapy.
- Analysis of postdialysis data from patients with naturally occurring high hematocrit levels.
Main Results:
- Epoetin therapy leads to marked improvements in patient well-being as anemia is reduced.
- Fears of accelerated hypertension and increased fistula clotting associated with epoetin therapy are largely unfounded.
- No significant increase in fistula clotting was reported in a phase IV postmarketing study; however, needle size requires consideration to prevent hemolysis at higher hematocrit levels.
Conclusions:
- Optimizing hematocrit levels in dialysis patients receiving epoetin therapy is crucial for improved outcomes.
- Concerns about fistula clotting due to postdialysis inspissation are alleviated by existing data.
- Careful consideration of factors like venous needle size is important when aiming for higher hematocrit levels to prevent complications like hemolysis.